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ABSTRACT 
Objective: Despite its sensitivity to light, atenolol has been manufactured as a film-coated tablet with normal blister packaging by several 
pharmaceutical companies in Bangladesh. The aim of this study was to investigate the extent of light-induced potency degradation of a randomly 
selected film coated brand of atenolol. 
Methods: Atenolol tablets were exposed to different lighting conditions such as normal room light, direct sunlight and different incandescent lights 
(25W and 40W). Subsequently, UV spectroscopy technique was employed to determine the relative reduction of light absorbance compared to their 
respective controls. Thereafter, photolytic degradation was calculated by means of the potency reduction of tablets. 
Results: In all lighting conditions, atenolol tablets underwent exposure dependent gradual decrease in potency. Except for normal room light 
condition, a significant decrease in potency was found even after 4 to 6 h of exposure to all lighting conditions. After 6 h, potency reduction was 
found at 40-47%, 26-38% and 34-36% in the samples exposed to direct sunlight, 25 W bulb, and 40 W bulb respectively. Although the shelf life of 
the film coated tables was 2 y, surprisingly, statistically significant reduction in potency was observed within only 30 d in room light condition.  
Conclusion: In order to protect from light, blister packaging is not sufficient for film coated atenolol tablets. Photo-stability of all brands of atenolol 
must be ensured either by protective packaging materials or by optimizing the formulations. 
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A common medical condition, hypertension (HTN), or high blood 
pressure (HBP), is affecting more than 75% of older people(>70 y), 
whereas one-third of a young adult has been estimated suffering 
from HBP [1]. According to a new study [2], it was the biggest risk 
factor that led to the global disease burden in 2010. Moreover, 
hypertensive heart disease and HTN contribute about 17.3/100000 
of the yearly age-adjusted deaths as mentioned in the US 
government's Centers for Disease Control and Prevention (CDC) [3] 
lists. Most common comorbidities of HTN patients include higher 
levels of serum cholesterol, low-density lipoprotein (LDL), 
triglycerides and body mass index (BMI) [4]. In medical literature, 
HTN often coined as ‘silent killer’ since it does not cause any severe 
symptoms to appear [5]. However, a cross-sectional study performed 
in Jammu has concluded that most of the hypertensive patients 
(72.5%) were concerned about the symptoms [6], alternatively, 
another study conducted in Kerala has suggested that the majority of 
hypertensive patients lack the knowledge on stroke prevention [7]. 
Although cardiac walking and laughter therapy has recently been 
found as maintaining optimum blood pressure in HTN patients [8, 9], 
one of the major successes in medicine in the past decades was the 
treatment of HTN. The striking therapeutic advancement provided a 
greater capability of controlling blood pressure in hypertensive 
patients [10]. Interestingly, recent studies have revealed that advanced 
drug formulation techniques such as transdermal system, floating 
bead formulations, and bi-layer tablet formulations can be used for 
more prolonged and effective treatment of HTN [11-13]. 
Since 1960, β-blockers has been using as the most promising 
treatment of HTN compared to existing antihypertensive drugs 
available, including guanethidine, ganglionic blocker or methyldopa 
[3]. A selective β1 receptor antagonist, atenolol, was developed in 
1976 as a better alternative for non-selective β-blocker propranolol in 
the treatment of HTN. In addition, being unable to cross the blood-
brain barrier, it has drawn more attraction exerting less central nervous 
system side effects [14]. Atenolol, considering as the most widely used β-
adrenergic receptor blocking agent, has often been the drug of choice for 
reference in randomized controlled trials of HTN [15]. 
Currently, drug photo-stability investigation has drawn much 
attention since photolytic degradation can reduce the potency of a 
drug and also form toxic degradation products contributing in adverse 
effects. As a consequence, light-sensitive drugs and adjuvants are 
recommended to be protected from light during storage [16] 
accomplishing by using an opaque blister, opaque gelatin shell or 
opaque film packaging for tablets or capsules [17]. Besides, a reflective 
pigment or a pharmaceutical dye with the same absorption spectrum 
as the drug principle can be added in the formulation to obtain the 
opaqueness [18]. Photophysical and photochemical properties of a 
drug are indispensable to predict phototoxic properties and also to 
evaluate product quality. Photo-stability and phototoxicity of some 
classes of drugs have been studied [19]. Although atenolol has been 
reported as photosensitive [16], in Bangladesh, many brands of this 
drug have been manufacturing with transparent blister packaging or 
as film coated. In our current study, we investigated the extent of light-
induced potency degradation of a randomly selected film coated brand 
of atenolol after exposing to different lighting conditions. 
MATERIALS AND METHODS 
Photo-stability study of drug formulations is carried out assuming that 
the finished product will experience various lighting conditions such 
as normal room light, direct sunlight and artificial electric bulb light. 
Noteworthy, reasonable sensitivity, simplicity and cost-effectiveness 
have lead spectrophotometric techniques to be the most preferred 
method for routine analysis [20]. As a consequence, we treated our 
test brand of atenolol by different light sources to determine potency 
reduction employing UV spectrophotometry.  
Sample collection  
The study was conducted using a randomly selected brand of 
atenolol (batch number: 14004) tablet formulation, purchased from 
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a local pharmacy in Dhaka, Bangladesh. All tablets were 
manufactured in blister packs, containing 50 mg Atenolol each. In 
order to ensure reproducibility of the results, tablets were divided 
into three different groups (A, B, and C). In each group of tablets, 
some were kept as a control in a light-protected amber container, 
and the rest were treated at different exposure conditions. 
Preparation of standard curve 
0.1N sulfuric acid (H2SO4) solution was prepared from 98% w/v 
stock solution of sulfuric acid (Analar, United Kingdom) to 
determine the wavelength of maximum absorption, λmax (223.5 nm) 
using a reference standard of Atenolol (99.5% potency) supplied by 
ACI pharmaceuticals, Bangladesh. Nine different concentrations 
from 0.001 to 0.009 mg/ml of atenolol were prepared by using 0.1 N 
H2SO4. Subsequently, the absorbances were measured for each 
concentration at λmax (223.5 nm), and the graph was plotted against 
their respective concentrations to yield the standard curve (as 
shown in fig. 1) with the following equation:/Where, y = absorbance, 
x = concentration of the drug (mg/ml). Potencies of atenolol 
formulations after different treatment conditions were calculated 




Fig. 1: Plot showing a straight line for absorbance with respect to concentration for atenolol. The R2represents coefficient of 
determination 
 
Normal room light exposure 
The experiment was designed to observe any change in potency of 
atenolol tablet formulation following exposure to normal room light 
condition for 60 d. From each group (A, B and C) of tablets, 10 were 
kept in a light protected container as control and 40 tablets were 
kept under a normal room light condition for 60 d. Those were 
analyzed by removing 10 tablets each time in 15, 30, 45 and 60 d to 
determine their level of potency by UV spectroscopy (Shimadzu UV 
1800, Japan).  
Direct sunlight exposure 
Experiments were performed to study how direct sunlight affects 
the potency of light unprotected atenolol tablet formulations. From 
each group (A, B and C), 10 tablets were kept in a light protected 
container as control and 30 tablets were exposed to direct sunlight 
for 7.5 h at a stretch. The minimum and maximum average 
temperatures of the experiment days were recorded as 30 and 32 ˚C. 
Every two hours intervals 10 tablets were removed and 
temperatures were recorded by a thermometer (Midwest Home 
brewing and Winemaking Supplies, USA) up to 6 h (as shown in 
table 1) to determine their potency level by UV spectroscopy. 
Exposure to incandescent light bulbs (25 W and 40 W) 
The same procedure was followed to determine the changes in the 
potency of atenolol tablet formulations after exposure to 25 W 
incandescent light bulbs (Philips, Bangladesh) and 40 W 
incandescent light bulbs (Philips, Bangladesh). Temperatures were 
also recorded similarly (table 2). 
 
Table 1: Withdrawal temperatures at different time intervals after exposure to direct sunlight 
No. of tablets from each group Collected sample Withdrawal intervals (h) Temperature ( °C) 
40 (10 for control) 10 2 30 
10 4 31 
10+10 (control) 6 32 
 
Table 2: Withdrawal temperatures at different time intervals after exposure to 25 W and 40 W bulbs 
Withdrawal intervals (h) Temperature ( °C) 
25 W 40 W 
2 27 30 
4 27 30 
6 30 32 
 
Assay procedure 
After termination of treatment, tablets from both controls and 
samples underwent the same analytical procedure. Those were 
crushed into powder and weighed in order to measure the average 
weight of the single respective tablet. Subsequently, that weighed 
powder was made into a solution by diluting 1000 times into 0.1N 
sulfuric acid. Absorbances of the solutions were then measured by 
UV spectroscopy and the respective potencies of each sample and 
control were calculated by standard curve calculation (fig. 1). 
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Statistical significance was studied with Students t-test. For all 
statistical analyses, a two-tailed p-value was measured, and it was 
presented for individual experiments considering significant when 
the value was less than 0.05 (*p<0.05, **p<0.01 and ***p<0.001).  
RESULTS AND DISCUSSION 
Loss of potency is the most luminous result of drug photo-
decomposition, which can turn a drug formulation therapeutically 
inactive. However, minor degradation of a drug product during 
storage and administration can lead to adverse effects, which is very 
common apparently [21]. Since the forced degradation of drug 
products differ in the mechanism of degradation reaction from 
normal condition [22], we followed both strategies to investigate the 
photosensitivity of atenolol more extensively.  
A common trend of gradual decrease in potency with higher 
duration of treatment has shown in all groups of samples in all 
treatment conditions (as shown in fig. 2, 3, 4 and 5). However, the 
extent of potency reduction varies in between groups and treatment 
conditions. 
Exposure to normal room light condition for 60 d resulted highly 
statistically significant (***p<0.001) decrease in potency (up to 23% 
approximately) of atenolol compared to control in both groups (fig. 
2). Although the samples exposed for 15 d to normal room light 
condition did not experience any significant change, those exposed 
for 30 and 45 d experienced a statistically significant reduction 
(**p<0.01, ***p<0.001) in potency (fig. 2). Minor variations of the 
extent of statistical significance for samples exposed for 30 and 45 d 
among different groups are because of different standard deviations. 
It could also be a result of variations in the purity of active 
pharmaceutical ingredient (API) among different tablets. Since the 
intensity of the radiation acts as a rate-limiting factor of photolytic 
degradation [23], undersized but not unusual, those minor 
differences in potency reduction among different groups could also 
be due to a nonhomogeneous mixing of API with excipients. 
 
 
Fig. 2: Potency of three different groups (A, B, and C) of a randomly selected brand of atenolol tablet formulation after exposure to normal 
room light for 15, 30, 45 and 60 d. Results are presented as percent compared to control (unexposed sample), and each result is 
represented as mean±SD of triplicate experiments. Error bars indicate standard deviations. Asterisk indicates statistically significant 
change.*p<0.05, **p<0.01, ***p<0.001 
 
 
Fig. 3: Potency of three different groups (A, B, and C) of a randomly selected brand of atenolol tablet formulation after exposure to direct 
sunlight for 2, 4 and 6 h. Results are presented as percent compared to control (unexposed sample), and each result is represented as 
mean±SD of triplicate experiments. Error bars indicate standard deviations. Asterisk indicates statistically significant change.*p<0.05, 
**p<0.01, ***p<0.001 
 
Forced photolytic degradation was carried out by exposing the 
samples and controls to direct sunlight and electric bulb lights. As 
shown in the fig. 3, all the three groups of the sample have shown a 
similar trend of gradual decrease in potency (40-47 %) with 
exposure time. Additionally, samples exposed for 4 and 6 h to direct 
sunlight have found statistically significantly decreased in potency 
(**p<0.01, ***p<0.001) compared to respective controls in both 
groups (fig. 3). 
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Fig. 4: Potency of three different groups (A, B, and C) of a randomly selected brand of atenolol tablet formulation after exposure to 25 W 
incandescent light bulbs for 2, 4 and 6 h. Results are presented as percent compared to control (unexposed sample) and each result is 
represented as mean±SD of triplicate experiments. Error bars indicate standard deviations. Asterisk indicates statistically significant 
change.*p<0.05, **p<0.01, ***p<0.001 
 
 
Fig. 5: Potency of three different groups (A, B, and C) of a randomly selected brand of atenolol tablet formulation after exposure to 40 W 
incandescent light bulbs for 2, 4 and 6 h. Results are presented as percent compared to control (unexposed sample), and each result is 
represented as mean±SD of triplicate experiments. Error bars indicate standard deviations. Asterisk indicates statistically significant 
change.*p<0.05, **p<0.01, ***p<0.001 
 
Although exposure to 25 W and 40 W incandescent lights resulted in 
a similar motif of gradual degradation of the potency of atenolol with 
time in both cases and in all sample groups, notably, exposure to 40 
W bulbs experienced more significant degradation of potency (34-
36%) for 6 h exposure. However, in both cases, samples exposed to 4 
and 6 h have shown a highly significant reduction (***p<0.001) in 
potency compared to their respective controls. Combination of all 
results displays a very clear exposure dependent pattern of 
photolytic degradation of a randomly selected film coated brand of 
atenolol after exposure to any lighting condition (normal room light, 
direct sunlight and incandescent bulb light), warning that film 
coating of atenolol with normal blister packaging is not enough to 
protect it from photolytic degradation.  
Apart from therapeutic inactivity by reducing potency, photolytic 
degradation of atenolol can also contribute to alteration of 
physicochemical properties of the formulation [21]. Moreover, photolytic 
degradation of atenolol produces a minor toxic product, 2-(4-
hydroxyphenyl) acetamide, which may cause gastrointestinal irritation, 
nausea, vomiting, and diarrhea [16]. Therefore atenolol should be 
manufactured with adequate light protection in order to achieve the 
desired therapeutic effect and to avoid adverse effects as well.  
Notwithstanding that it is possible to implement by replacing the 
packaging materials with light protective ones, changes in formulation 
could also be another path to address this problem. The Photolytic 
degradation of a tablet mostly takes place on the upper surface that 
contacts with incident light [21]. Alternatively, irrespective of exposure 
time, the interior of the tablet remains almost unaffected since light 
radiation barely reaches there. Therefore, the factors influencing depth 
of light penetration, for example, the thickness of powder bed, particle 
size, color, and thickness could also be optimized to avoid photolytic 
degradation of a tablet [17].  
CONCLUSION 
Several different brands of atenolol are available in the pharma 
market of Bangladesh, which have not been manufactured with 
proper light protection. Critical analysis of the results of our current 
study and knowledge from literature allow us to conclude that 
atenolol must be manufactured with sufficient light protection to 
retain therapeutic activity throughout its shelf life. Formulation 
difficulties for light-sensitive drugs are not uncommon. However, a 
good understanding of photolytic degradation mechanism can 
contribute to accomplishing optimum stability of a formulation.  
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